DARE
Dare Bioscience Inc
$
2.040
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.0602
Open
2.030
VWAP
2.05
Vol
38.96K
Mkt Cap
17.97M
Low
2.030
Amount
79.71K
EV/EBITDA(TTM)
--
Total Shares
101.09M
EV
14.87M
EV/OCF(TTM)
2.21
P/S(TTM)
509.66
Dare Bioscience, Inc. is a biopharmaceutical company. The Company's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
141.50K
+530.57%
--
--
147.25K
+253.2%
--
--
532.25K
-936.21%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Daré Bioscience, Inc. (DARE) for FY2025, with the revenue forecasts being adjusted by 0.75% over the past three months. During the same period, the stock price has changed by -29.41%.
Revenue Estimates for FY2025
Revise Upward
+0.75%
In Past 3 Month
Stock Price
Go Down
-29.41%
In Past 3 Month
3 Analyst Rating
255.39% Upside
Wall Street analysts forecast DARE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DARE is 7.25 USD with a low forecast of 2.50 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
255.39% Upside
Current: 2.040
Low
2.50
Averages
7.25
High
12.00
255.39% Upside
Current: 2.040
Low
2.50
Averages
7.25
High
12.00
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$12
2025-04-01
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$12
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$12
2024-12-17
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$12
2024-12-17
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$12
2024-11-15
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$12
2024-11-15
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$12
2024-10-24
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$12
2024-10-24
Reiterates
Strong Buy
Reason
Jones Trading
Catherine Novack
Strong Buy
Maintains
$5 → $13
2024-08-16
Reason
Jones Trading
Catherine Novack
Price Target
$5 → $13
2024-08-16
Maintains
Strong Buy
Reason
Maxim Group
Caroline Palomeque
Strong Buy
to
Hold
Downgrades
n/a
2024-08-14
Reason
Maxim Group
Caroline Palomeque
Price Target
n/a
2024-08-14
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Dare Bioscience Inc (DARE.O) is -0.83, compared to its 5-year average forward P/E of -2.95. For a more detailed relative valuation and DCF analysis to assess Dare Bioscience Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.95
Current PE
-0.83
Overvalued PE
-0.69
Undervalued PE
-5.21
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
18.59
Current PS
9.32
Overvalued PS
38.82
Undervalued PS
-1.63
Financials
Annual
Quarterly
FY2025Q1
YoY :
+173.35%
25.43K
Total Revenue
FY2025Q1
YoY :
-23.93%
-4.58M
Operating Profit
FY2025Q1
YoY :
-35.19%
-4.38M
Net Income after Tax
FY2025Q1
YoY :
-38.27%
-0.50
EPS - Diluted
FY2025Q1
YoY :
-17.48%
-5.63M
Free Cash Flow
FY2025Q1
YoY :
+471.43%
100.00
Gross Profit Margin - %
FY2025Q1
23.21K
FCF Margin - %
FY2025Q1
YoY :
-76.29%
-17.22K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DARE News & Events
Events Timeline
2025-07-29 (ET)
2025-07-29
08:17:09
Dare Bioscience, Rosy Wellness launch first phase to support DARE to PLAY
2025-07-14 (ET)
2025-07-14
08:03:47
Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene
2025-07-11 (ET)
2025-07-11
08:12:10
Dare Bioscience receives $6M non-dilutive grant installment
Sign Up For More Events
Sign Up For More Events
News
1.0
07-21NewsfilterUPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar
2.0
07-15TipRanks3 Penny Stocks to Watch Now, 7/15/25
4.5
07-15BenzingaUS Stocks Close Mixed As Tariff Concerns Rise: Investor Sentiment Improves, Fear & Greed Index Remains In 'Extreme Greed' Zone
Sign Up For More News
People Also Watch
COCH
Envoy Medical Inc
1.470
USD
0.00%
HVT.A
Haverty Furniture Companies Inc
22.900
USD
0.00%
FOXX
Foxx Development Holdings Inc
6.680
USD
+1.21%
BCAB
Bioatla Inc
0.370
USD
0.00%
SWIN
Solowin Holdings Ltd
4.730
USD
-4.64%
WKHS
Workhorse Group Inc
1.790
USD
+3.47%
HUIZ
Huize Holding Ltd
2.490
USD
+1.63%
ZOOZ
Zooz Power Ltd
1.990
USD
+4.74%
JOB
GEE Group Inc
0.212
USD
+1.43%
NXPL
NextPlat Corp
0.770
USD
0.00%
FAQ
What is Dare Bioscience Inc (DARE) stock price today?
The current price of DARE is 2.04 USD — it has increased 0.49 % in the last trading day.
What is Dare Bioscience Inc (DARE)'s business?
What is the price predicton of DARE Stock?
What is Dare Bioscience Inc (DARE)'s revenue for the last quarter?
What is Dare Bioscience Inc (DARE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Dare Bioscience Inc (DARE)'s fundamentals?
How many employees does Dare Bioscience Inc (DARE). have?